Navigation Links
Findings could lead to a blood test for lung cancer

COLUMBUS, Ohio Researchers have identified characteristic patterns of molecules called microRNA (miRNA) in the blood of people with lung cancer that might reveal both the presence and aggressiveness of the disease, and perhaps who is at risk of developing it. These patterns may be detectable up to two years before the tumor is found by computed tomography (CT) scans.

The findings could lead to a blood test for lung cancer, according to a researcher with the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute who helped lead study.

"We found patterns of abnormal microRNAs in the plasma of people with lung cancer and showed that it might be possible to use these patterns to detect lung cancer in a blood sample," says principal investigator Dr. Carlo M. Croce, professor of molecular virology, immunology and medical genetics, and director of the Human Cancer Genetics program.

"These abnormal microRNAs were present in blood serum well before the tumors were detected by a sensitive method such as spiral CT scan, suggesting they might have strong predictive, diagnostic and prognostic potential."

The findings were published in a recent issue of the Proceedings of the National Academy of Sciences.

Croce and his collaborators initially identified the molecular patterns in tissue samples collected from patients participating in a clinical trial examining the use of spiral CT scans to screen for lung cancer. The trial involved 1,035 individuals aged 50 years or older who had smoked at least a pack of cigarettes a day for 20 years or more. All patients underwent a CT scan every year for five years and provided blood, sputum and urine samples.

The researchers initially analyzed 28 tumor samples and 24 samples of normal-lung tissue for their miRNA profiles. They identified miRNAs that could discriminate between lung tumor and normal lung tissue. They also found patterns of miRNAs that distinguished tumors with faster growth rates and that correlated with poor disease-free survival.

Then Croce and his colleagues analyzed blood samples that had been collected more than a year before the individual's lung cancer was detected by spiral CT. They discovered a signature of 15 miRNAs that could identify 18 of 20 individuals whose cancer was later detected by spiral CT.

To verify that finding, they applied the signature to a second set of blood samples collected during a similar but unrelated lung-cancer trial. Here, the signature correctly identified 12 of 15 patients whose lung tumors were detected more than a year later by spiral CT. The researchers estimated that the signature were detectable in blood up to 28 months prior to spiral CT detection.

The researchers also found miRNA signatures in the blood that were associated with the following:

  • Lung-cancer diagnosis a signature identified 16 of 19 patients with lung cancer in set one, and 12 of 16 patients in set two.
  • Poor prognosis a signature identified five of five patients with poor prognosis in set one; four of five in set two.
  • Good prognosis a signature identified five of 15 patients in set one, and five of 11 patients in set two.

"Our goal was to identify biomarkers that could predict tumor development and prognosis to improve lung-cancer diagnosis and treatment," Croce says. "Overall, these findings strengthen the observation that circulating miRNA in plasma is detectable well before clinical disease detection by spiral CT, indicating the possibility of identifying high-risk patients on the basis of miRNA profiling."


Contact: Darrell E. Ward
Ohio State University Medical Center

Related medicine news :

1. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
2. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
3. VARI findings may help patients with deadly kidney cancer
4. UMass Lowell researchers findings suggest new ways to diagnose and treat Alzheimers
5. Research findings expected to ease treatment of low neutrophil counts in cancer patients
6. Cedars-Sinai Heart Institute physicians present findings at ACC scientific meeting
7. Research findings underscore needed action to safeguard lungs of young cancer survivors
8. Those with allergic asthma face double trouble during flu season, UT Southwestern findings suggest
9. Findings suggest optimal dose
10. VARI findings could help diagnose and treat liver cancer
11. Brain MRI in children: Incidental findings yield disclosure dilemmas for doctors, patients
Post Your Comments:
(Date:10/12/2015)... ... October 13, 2015 , ... Career Step, an online ... of its new Professional Medical Coding and Billing with Applied PCS career training ... ICD-10-PCS code sets, earn the Certified Professional Coder (CPC) and Certified Coding Associate ...
(Date:10/12/2015)... , ... October 12, 2015 , ... ... August 19, 2015, high school aged female athletes, particularly in the area of ... repetitive motion and mechanical overuse injuries than male peers in the same age ...
(Date:10/12/2015)... Los Angeles, CA (PRWEB) , ... October 12, 2015 , ... ... 7th, the Fire Chief for the city of San Antonio, Texas recommended that any ... retrofitted to incorporate these important safety systems going forward. The article explains that it ...
(Date:10/12/2015)... ... October 12, 2015 , ... AcousticSheep LLC, ... Cleveland Clinic in honor of Breast Cancer Awareness Month. During the month ... will donate a SleepPhones® Classic product to a breast cancer patient at the ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... On July ... MN. Their mission: To paddle the entire 2,320-miles of river to the Gulf of ... halfway done with the monumental journey, with two months remaining for a November 22nd ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... October 12, 2015 ... to grow at 7.2% CAGR, microscopy market ... rising focus on nanotechnology, technological advancements, and ... report available with ... . --> Complete report on ...
(Date:10/12/2015)...   Royal Philips (NYSE: PHG, AEX: PHIA), ... a collaboration with Genomic Health , Inc. (NASDAQ: ... diagnostic tests, to leverage Philips digital pathology tools in ... testing processes.    --> ... samples and plays a crucial role in the diagnosis ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: ... District of Delaware granted the Company,s ... Pharmaceuticals, Abbreviated New Drug Application (ANDA) No. 205299 to market ... (buprenorphine and naloxone) Sublingual Film (CIII) in the ... --> Since August 2013, Indivior has received Paragraph IV ...
Breaking Medicine Technology: